PRME Prime Medicine, Inc.
Prime Medicine, Inc., a biotechnology company, engages in delivering genetic medicines to address the spectrum of diseases by deploying gene editing technology in the United States. Its lead therapeutic product candidate…
Industry Peers
Biotechnology| Headline | Source | Time |
|---|---|---|
Older | ||
 Temporary Weakness in Intellia Stock Seems Like a Buying Opportunity Here's how to play leading gene-editing stocks as Anthropic's AI tools make progress in the gene-editing space. | ||
Prime Medicine stock surges on FDA IND clearance Investing.com -- Prime Medicine Inc (NASDAQ:PRME) shares gained over 12% in after-hours trading Thursday following the FDA's clearance of the company's Investigational New Drug application for PM647, an in vivo gene editing therapy for Alpha-1 Antitrypsin Deficiency. | ||
Anthropic AI Discovery Gene-Editing Stocks Falling Anthropic says Claude identified a novel enzyme system with characteristics reminiscent of CRISPR | ||
 CRSP, NTLA, BEAM, PRME, EDIT Shares Slip — Did Claude Just Spook Gene-Editing Stocks? CRSP shares closed down 6% on Wednesday, while PRME and EDIT stocks declined 12% and 8%, respectively. | ||
 Gene-Editing Powerhouse And Its Rivals Surge Toward A Breakout Crispr stock, alongside other gene-editing equities, pulled a bullish move Thursday — bounding for a breakout from a cup-with-handle base. | ||
 Prime Medicine, Inc. (PRME) Reports Q2 Loss, Misses Revenue Estimates Prime Medicine, Inc. (PRME) delivered earnings and revenue surprises of 0.00% and -73.76%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock? | ||
 Prime Medicine, Inc. (PRME) May Report Negative Earnings: Know the Trend Ahead of Q2 Release Prime Medicine, Inc. (PRME) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. | ||
 Scribe’s Genetic Editing Aims to Prevent Heart Attacks Scribe Therapeutics shares are up 30% since it raised $125 million in its initial public offering Friday. The cash will fund three clinical trials testing whether Scribe’s one-time treatments can halve the risk of heart attacks and strokes. Scribe’s therapies turn off the genetic instructions leading to high levels of damaging lipids, without having to cut a gene’s DNA strands like other one-shot genetic treatments in the clinic. | ||
 Bank of America Securities Maintains Buy Rating for Beam Therapeutics (BEAM) Beam Therapeutics Inc. (NASDAQ:BEAM) is one of the 10 affordable biotech stocks to buy right now. On July 8, Alec Stranahan from Bank of America Securities reaffirmed his Buy rating for Beam Therapeutics Inc. (NASDAQ:BEAM), following a favorable resolution announced by Prime Medicine regarding its arbitration with Beam. Stranahan forecasted a target price of $47, […] | ||
 Prime Medicine (PRME) Reaches Positive Resolution to Arbitration with Beam Therapeutics Prime Medicine, Inc. (NASDAQ:PRME) is one of the best strong buy penny stocks to invest in now. Prime Medicine, Inc. (NASDAQ:PRME) announced on July 8 a positive, binding resolution of its previously disclosed arbitration with Beam Therapeutics, Inc. relating to the parties’ 2019 Collaboration and License Agreement. The company reported that the Tribunal declared that PM647, […] | ||